文献速递免疫规划卫生政策与健康促进

使用标准化成本核算框架预测马拉维国家免疫规划引入伤寒结合疫苗(TCV)的成本

Projecting the cost of introducing typhoid conjugate vaccine (TCV) in the national immunization program in Malawi using a standardized costing framework.
PubMed 文献 · Vaccine · 2022-02-10

马拉维计划于2022年末在国家免疫规划中引入伤寒结合疫苗(TCV),先对9月龄至15岁儿童开展全国接种活动,之后通过常规免疫在9月龄提供。

要点

  • 马拉维计划2022年末引入TCV,先开展9月龄至15岁儿童全国接种活动,之后常规免疫9月龄接种。
  • 超过三分之二的总成本为经常性成本,主要驱动因素为疫苗和注射用品采购及服务提供。

核心结论

  • 超过三分之二的总成本由经常性成本构成。
  • 主要成本驱动因素包括疫苗和注射用品采购以及服务提供成本。

研究设计与样本

  • 本研究为成本核算分析,从政府视角预测马拉维引入TCV的增量成本。
  • 使用国际疫苗研究所与世界卫生组织合作、由Levin & Morgan开发的成本核算工具。
  • 利用通过与马拉维扩大免疫规划团队各级代表关键知情人访谈收集的一手和二手数据。

主要发现

  • 超过三分之二的总成本为经常性成本。
  • 主要成本驱动因素包括疫苗和注射用品采购以及服务提供成本。
  • 在不含疫苗成本的情况下,每名免疫儿童的成本估计远低于1美元。

临床怎么用

  • 分析结果可用于评估在马拉维引入TCV的经济影响。
  • 分析强调的主要成本驱动因素可为该区域决策者评估在其国家免疫规划中引入TCV的价值和可行性提供信息。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a substantial typhoid burden in sub-Saharan Africa, and TCV has been introduced in two African countries to date. Decision-makers in Malawi decided to introduce TCV and applied for financial support from Gavi, the Vaccine Alliance in 2020. The current plan is to introduce TCV as part of the national immunization program in late 2022. The introduction will include a nationwide campaign targeting all children aged 9 months to 15 years. Following the campaign, TCV will be provided through routine immunization at 9 months. This study aims to estimate the cost of TCV introduction and recurrent delivery as part of the national immunization program. METHODS: This costing analysis is conducted from the government's perspective and focuses on projecting the incremental cost of TCV introduction and delivery for Malawi's existing immunization program before vaccine introduction. The study uses a costing tool developed by Levin & Morgan through a partnership between the International Vaccine Institute and the World Health Organization and leverages primary and secondary data collected through key informant interviews with representatives of the Malawi Expanded Programme on Immunization team at various levels. RESULTS: The total financial and economic costs of TCV introduction over three years in Malawi are projected to be US$8.5 million and US$29.8 million, respectively. More than two-thirds of the total cost is made up of recurrent costs. Major cost drivers include the procurement of vaccines and injection supplies and service delivery costs. Without vaccine cost, we estimate the cost per child immunized to be substantially lower than US$1. DISCUSSION: Findings from this analysis may be used to assess the economic implications of introducing TCV in Malawi. Major cost drivers highlighted by the analysis may also inform decision-makers in the region as they assess the value and feasibility of TCV introduction in their national immunization program.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Debellut F, Mkisi R, Masoo V, et al. Projecting the cost of introducing typhoid conjugate vaccine (TCV) in the national immunization program in Malawi using a standardized costing framework. Vaccine. 2022. PMID: 35153097. doi:10.1016/j.vaccine.2022.02.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。